Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Multiple Sclerosis, Neuromyelitis Optica
Interventions: Not listed
Lead sponsor: Jagannadha R Avasarala; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Single Level Lumbar Decompression and Fusion Spine Surgery
Interventions: Multimodal Analgesia Treatment, Standard of Care Pain Management Protocol; Other
Lead sponsor: OrthoCarolina Research Institute, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: biologic sample preservation procedure; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 1,294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 292
States / cities: Fort Smith, Arkansas • Berkeley, California • Burbank, California + 192 more

Conditions: Coronary Disease
Interventions: CoStar Paclitaxel Drug Eluting Coronary Stent System, TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent; Device
Lead sponsor: Cordis US Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 1,701 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: Durham, North Carolina • Cincinnati, Ohio

Conditions: Bladder Cancer
Interventions: Nivolumab; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 2
States / cities: Tampa, Florida • Salt Lake City, Utah

Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Interventions: paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, erlotinib hydrochloride; Drug · Biological
Lead sponsor: University of Washington; Other
Eligibility: Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 17
States / cities: Anchorage, Alaska • Yuma, Arizona • Lewiston, Idaho + 12 more

Conditions: Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor, Ependymoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Primary CNS Tumor
Interventions: Indoximod, Temozolomide, Conformal Radiation, Cyclophosphamide, Etoposide; Drug · Radiation
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 3 Years to 21 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 5
States / cities: Aurora, Colorado • Orlando, Florida • Atlanta, Georgia + 2 more

Conditions: Anemia, Small Bowel Bleeding, Angioectasias
Interventions: Tranexamic Acid (TXA) treatment, Placebo; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Sleep Apnea, Sleep Disordered Breathing
Interventions: 14 days of placebo therapy, 14 days of CPAP therapy; Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 90 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Cough
Interventions: GSK5464714- Camlipixant; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Rebecca Torguson; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Neoplasm, Neoplasm Metastasis
Interventions: Autologous T cells, Interleukin-2; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Phenylketonuria (PKU)
Interventions: MZE782, Placebo; Drug · Other
Lead sponsor: Maze Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Oakland, California • Palo Alto, California • Chicago, Illinois + 4 more

Conditions: Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Interventions: SPT-300, Placebo; Drug
Lead sponsor: Seaport Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 29
States / cities: Chino, California • Garden Grove, California • Glendale, California + 25 more

Conditions: Sickle Cell Disease
Interventions: Digital app and information system; Other
Lead sponsor: Makerere University; Other
Eligibility: Up to 5 Years
Enrollment: 24,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Covid19, Infectious Disease
Interventions: A $10 Survey Incentive, A $20 Survey Incentive, Emphasis of Government Involvement, Emphasis of Academic Researchers Involvement, Cost-Benefit Frame, Duty Frame, Racial/Ethnic Frame, No Messaging; Behavioral
Lead sponsor: Harvard University; Other
Eligibility: 18 Years and older
Enrollment: 561 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Bloomington, Minnesota • Columbia Heights, Minnesota • Eden Prairie, Minnesota + 5 more

Conditions: Myeloid Chimerism
Interventions: CliniMACS CD34 Reagent; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2037
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Neoplasms
Interventions: Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner; Device
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Bone Sarcomas
Interventions: Zanzalintinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mouth Diseases
Interventions: detection of oral pathology; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1,004 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2026
U.S. locations: 1
States / cities: Irvine, California

Conditions: Intracranial Atherosclerosis
Interventions: Feraheme; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Schizophrenia
Interventions: BF2.649, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Alzheimer Disease, Early Onset, MCI, Aging, Mild Cognitive Impairment, Neurocognitive Disorder, Cognitive Impairment, Cognitive Change
Interventions: physical exercise alone (PES) first, cognitive exercise alone (iCE) first, interactive Physical and Cognitive Exercise (iPACES™); Behavioral · Device
Lead sponsor: Union College, New York; Other
Eligibility: 50 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Schenectady, New York

Conditions: HIV Infections
Interventions: Zalcitabine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 3 Months to 11 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Nutley, New Jersey

Search by objective public record fields.

MS and NMOSD in African-Americans

Multimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study

S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)

Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Tranexamic Acid for The Management of Bleeding Gastrointestinal Angioectasias

Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea

A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants

Registry Experience at the Washington Hospital Center, DES - Endeavor for Myocardial Infarction

Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy

A Study of MZE782 in Adults With PKU

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

Development and Evaluation of an Information Management System and Communication System for Population-wide Point-of-care Infant Sickle Cell Disease Screening

Minnesota COVID-19 Testing Project

Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels

Comparison of Stationary Breast Tomosynthesis and 2-D Digital Mammography in Patients With Known Breast Lesions

A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)

Optical Sensor for Photodynamic Detection of Oral Pathology

Predicting Stroke Risk in ICAD With Novel MRI

Study to Demonstrate Cognitive Enhancing Effects of BF2.649

The Interactive Physical and Cognitive Exercise System

An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies